At YD BioLabs, we are pleased to announce the signing of a strategic collaboration agreement (MOU) with BiOptic Inc., a leading molecular diagnostics company. This partnership aims to accelerate the development of rapid, efficient, and environmentally friendly nucleic acid molecular labeling and diagnostic solutions.
By integrating our proprietary enzyme-based nucleic acid and probe synthesis technology with BiOptic’s advanced molecular diagnostic platforms, we will jointly create high-performance reagents with enhanced stability and customizability. This collaboration will also significantly shorten development timelines, driving faster innovation in precision diagnostics.
Our enzyme-driven approach eliminates the need for large volumes of toxic chemical solvents, reducing waste and minimizing environmental impact. This highlights our shared commitment to sustainability and the ESG values of green manufacturing.
This strategic alliance marks a major milestone for YD BioLabs in advancing both commercialization and international collaboration.
Media Coverage:
- Economic Daily News (UDN): Coverage of the YD BioLabs and BiOptic Inc. MOU on next-generation green molecular labeling and diagnostics. Read more ›
- Money-Link News: Highlights how the collaboration shortens development cycles and enhances probe performance for diagnostic applications. Read more ›
- Global Bio & Investment: Introduces YD BioLabs’ NGDS platform, developed by Dr. Cheng-Yao Chen, enabling “printer-like” DNA synthesis for diagnostics, sequencing, synthetic biology, and data storage. Read more ›
